How big is Tonix Pharmaceuticals Holding Corp.?

As of Jun 18, Tonix Pharmaceuticals Holding Corp. has a market capitalization of 256.91 million, with net sales of 10.04 million and a net profit of -131.93 million over the latest four quarters. As of Dec 24, shareholder's funds are 139.56 million, and total assets are 162.89 million.

As of Jun 18, Tonix Pharmaceuticals Holding Corp. has a market capitalization of 256.91 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 24, the sum of net sales for the latest four quarters is 10.04 million, while the sum of net profit for the same period is -131.93 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 139.56 million, and total assets amount to 162.89 million.

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders. As of March 2025, it reported net sales of $2 million and a net loss of $17 million, with a market cap of $256.91 million.

Overview:<BR>Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders, including fibromyalgia and post-traumatic stress disorder, and operates within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 256.91 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.73<BR>- Return on Equity: -38.82%<BR>- Price to Book: 1.42<BR><BR>Contact Details:<BR>- Address: 28 MAIN STREET, CHATHAM NJ: 07928<BR>- Tel: 1 212 9809155<BR>- Fax: 1 212 9235700<BR>- Website: https://www.tonixpharma.com/

Should I buy, sell or hold Tonix Pharmaceuticals Holding Corp.?

Who are in the management team of Tonix Pharmaceuticals Holding Corp.?

As of March 2022, the management team of Tonix Pharmaceuticals includes Dr. Seth Lederman as Chairman, President, and CEO, with Mr. James Treco as Lead Independent Director, and Independent Directors Mr. Richard Bagger, Ms. Margaret Bell, Dr. Daniel Goodman, and Brig. Gen. (Retd.) David Grange.

As of March 2022, the management team of Tonix Pharmaceuticals Holding Corp. includes Dr. Seth Lederman, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. James Treco is the Lead Independent Director. The board also consists of Mr. Richard Bagger, Ms. Margaret Bell, Dr. Daniel Goodman, and Brig. Gen. (Retd.) David Grange, all of whom are Independent Directors.

Is Tonix Pharmaceuticals Holding Corp. overvalued or undervalued?

As of November 9, 2023, Tonix Pharmaceuticals is considered risky and overvalued due to high financial ratios and negative returns, underperforming the S&P 500 significantly.

As of 9 November 2023, the valuation grade for Tonix Pharmaceuticals Holding Corp. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.65 and an EV to Sales ratio of 16.56, which are significantly high for a loss-making entity. Additionally, the company has a negative ROCE of -148.11% and a negative ROE of -38.82%, indicating poor returns on capital and equity.<BR><BR>In comparison to peers, Tonix's valuation ratios are concerning; for instance, Aytu Biopharma, Inc. has a fair P/E ratio of 2.46, while Tonix's P/E is not applicable due to its loss-making status. Other risky peers like Biofrontera, Inc. and Impel Pharmaceuticals, Inc. also reflect negative valuation metrics. Notably, Tonix's stock has underperformed against the S&P 500 across multiple periods, including a -29.20% return over the past month compared to the S&P 500's 2.33%, reinforcing the perception of overvaluation.

Is Tonix Pharmaceuticals Holding Corp. technically bullish or bearish?

As of September 10, 2025, Tonix Pharmaceuticals shows a mildly bullish trend driven by daily moving averages, but caution is advised due to bearish signals from the weekly MACD and Bollinger Bands, alongside underperformance against the S&P 500.

As of 10 September 2025, the technical trend for Tonix Pharmaceuticals Holding Corp. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, primarily driven by the daily moving averages indicating a positive trend. However, the weekly MACD remains bearish, and the Bollinger Bands are bearish across both weekly and monthly time frames, suggesting some caution. The KST shows a mixed signal with a mildly bullish monthly reading but a mildly bearish weekly reading. Overall, the stock has underperformed against the S&P 500 in the short term, with a 1-week return of -9.10% compared to the benchmark's 1.05%, and a 1-month return of -29.20% versus 2.33%.